鶹ýӰ

One in Nine Kids Have ADHD; Placebo Response in Trials; Befriending Former Patients

— News and commentary from the psychiatry world

MedpageToday
Illustration of a brain shaped maze.

Approximately one in nine U.S. children ever received an , CDC researchers reported. (Journal of Clinical Child & Adolescent Psychology)

The FDA approved once-daily, extended-release (Onyx XR) as adjunctive or monotherapy, making it the only liquid non-stimulant medication for ADHD, Tris Pharma said.

The investigational oral antidepressant NRX-101 reduced time to sustained remission from suicidality compared with lurasidone in people with , NRx Pharmaceuticals said.

Adjunctive, investigational first-in-class seltorexant met all primary and secondary endpoints in a phase III trial of people with , Johnson & Johnson announced.

Patients with major depressive disorder experienced the in randomized clinical trials, while patients with schizophrenia benefited the least. (JAMA Psychiatry)

Are higher Medicaid payments needed to ? (STAT)

The median time to remission among adults with a higher BMI exceeded 60 months, and the median time to relapse after remission was 30 months. (Psychological Medicine)

A new website to help manage neuropsychiatric symptoms of dementia. (KFF Health News)

Compared with white people in Pennsylvania, Black individuals who were less likely to receive naloxone, 2019-2021 data showed. (Addiction)

Psychoactive drugs like are "having a moment" but soon will face FDA review. (CBS News)

Letting addiction doctors is "not a good idea," a longtime methadone clinic industry leader said. (STAT)

Can retired psychiatrists ? (New York Times Magazine)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.